414 related articles for article (PubMed ID: 15964093)
1. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
2. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
[TBL] [Abstract][Full Text] [Related]
4. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
6. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
7. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
9. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
[TBL] [Abstract][Full Text] [Related]
10. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
12. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
13. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
14. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
15. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF
Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420
[TBL] [Abstract][Full Text] [Related]
16. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
[TBL] [Abstract][Full Text] [Related]
18. [A study on the treatment of chronic hepatitis B with YMDD mutation].
Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
[TBL] [Abstract][Full Text] [Related]
19. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
[TBL] [Abstract][Full Text] [Related]
20. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]